Medicine
Cosela 300 mg/20 mL powder for injection
Cosela 300 mg/20 mL powder for injection is a prescription medicine containing Trilaciclib for intravenous use, marketed by Pharmacosmos Therapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store COSELA vials at 20°C to 25°C (68°F to 77°F), excursions are permitted to…
Key facts
- Active ingredient (INN)
- Trilaciclib
- Brand
- Cosela
- Strength
- 300 mg/20 mL
- Dosage form
- Powder for injection
- Route
- Intravenous
- Packs
- 1 vial
- Marketing authorisation holder
- Pharmacosmos Therapeutics
- Manufacturers
- Pharmacosmos TherapeuticsG1 Therapeutics
- Origin register
- US FDA, United States
- Storage
- Store COSELA vials at 20°C to 25°C (68°F to 77°F), excursions are permitted to 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- V03AF12 Trilaciclib
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 12 February 2021
- Identifiers
- RxCUI 2479705, 2479710DailyMed set ID 4b06922c-498d-4871-a037-84a44e6a6b6c, b3179c19-78f3-4bf1-b73e-7f7638522ab1NDC 73462-101, 73594-0101Application NDA214200
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, glass in 1 carton / 20 mL in 1 vial, glass | 73594-0101-1 | Pharmacosmos Therapeutics | 25 August 2025 |
| 1 vial, glass in 1 carton / 20 mL in 1 vial, glass | 73462-101-01 | G1 Therapeutics | 12 February 2021 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Trilaciclib is a kinase inhibitor indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC). MedsAcross supplies Trilaciclib for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about TrilaciclibFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- COSELA prescribing information (Pharmacosmos Therapeutics) · U.S. National Library of Medicine, DailyMed
Need Cosela 300 mg/20 mL powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.